FCM
RXDX

Farallon Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Farallon Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change % 		Capital Flow Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,100,806
Closed -$118M – 189
2023
Q1 		$118M Buy
1,100,806
+955,706
+659% +$103M 0.65% 45
2022
Q4 		$16M Buy
+145,100
New +$16M 0.09% 87